Background: Gefitinib, a tyrosine kinase inhibitor, is effectively used in the targeted treatment
of malignant conditions. It suppresses the signal transduction cascades leading to cell …

Current standard therapy for advanced or metastatic non-small cell lung cancer (NSCLC)
includes chemotherapy, which is often associated with limited efficacy and toxicity. Thus …

Gefitinib (Iressa®) is a selective inhibitor of epidermal growth factor, a growth factor that
plays a pivotal role in the control of cell growth, apoptosis, and angiogenesis. Gefitinib is …

Targeted therapies are one of the latest innovative trends in cancer therapy. The epidermal
growth factor receptor (EGFR) is a target found in high concentrations in several solid tumors …

Gefitinib (Iressa™), the first commercially available epidermal growth factor receptor-tyrosine
kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally …

The epidermal growth factor receptor (EGFR) is recognized as a key modulator of tumor cell
function and is considered to be a viable drug target in a range of solid malignancies …

Several novel biologic agents have been designed to specifically inhibit different aspects of
tumor growth and progression. The epidermal growth factor receptor has a pivotal role in …

Gefitinib (Iressa™) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
that offers treatment for patients with locally advanced or metastatic non-small cell lung …

Epidermal growth factor receptor (EGFR) actively involves in modulation of various cancer
progression related mechanisms including angiogenesis, differentiation and migration …

Traditional cytotoxic anticancer therapies do not differentiate between tumour and host cells,
and research efforts have been focused on finding new agents that target tumour tissue …